Home Archives 2011

Yearly Archives: 2011

I will be giving a talk on “Using patent information to track globalization” at the ACS conference in Anaheim next week. The talk is part of the ACS Division of Chemistry and Law session on What Can Patent Information Do For Scientists, and is based on analysis of data from DrugPatentWatch. I look forward to meeting BiotechBlog readers who may be in attendance. For those who cannot make the event, my talk will be based on my work on globalization of pharmaceutical innovation.

Fortune magazine recently published an article on the growing trend of generic companies challenging pharmaceutical drug patents. I enjoyed working with the writer to help layout the industry landscape, and share my knowledge of drug patents and trends from DrugPatentWatch.com. It’s a good read, and it does an excellent job of laying out the legal, regulatory, and economic mess that the pharmaceutical industry has become.

    DrugPatentWatch.com is proud to announce the addition of a vital new feature to it's rich collection of drug patent intelligence tools: a Paragraph IV Certification newsfeed.

    I had the pleasure of serving as a judge for last year’s Biotech Humanitarian Award, and now it’s time for nomination’s for this year’s award. The Award will be given to an individual who, through their work in or support of biotechnology, is harnessing its potential to heal, fuel or feed the planet.

    In the words of BIO President and CEO Jim Greenwood.  “The Biotech Humanitarian Award offers us the opportunity to highlight our biotech innovators – the men and women who are pioneering real solutions to improve people’s lives and the health of our planet.”     The Humanitarian Award honors work that aims to reduce human suffering significantly or enhance the human experience in a way that has a clear and direct benefit to society.  Additional consideration will be given to approaches that are at a turning point and may potentially have immeasurable influence.

    Last year’s Award was bestowed upon Robert Klein, chairman of the governing board of the California Institute of Regenerative Medicine (CIRM).  Klein is best known as the author and Chairman of California’s Proposition 71, the $6 billion “California Stem Cell Research and Cures” ballot initiative, which supports research with a focus on pluripotent (embryonic) and progenitor stem cell research.  As chairman of CIRM, Klein manages the peer review and grant process for the $3 billion in stem cell research funding authorized by the Initiative.

    The inaugural Award was bestowed upon Dr. Jay Keasling, CEO of the Joint BioEnergy Institute, Professor of Chemical Engineering and Bioengineering at the University of California at Berkley and acting Deputy Director of the Lawrence Berkeley National Laboratory.  Keasling was honored for his break-through work in synthetic biology, which at commercial scale, will allow for lower cost access to first-line treatment for malaria, as well as significantly advance production of the next generation of biofuels.  Keasling has previously said that he expects the new malaria treatment to be released at the end of 2011 or in early 2012.

    The Award and a prize of $10,000 will be presented at the 2011 BIO International Convention, in Washington, DC on June 27-30, 2011.  Nominations are open to all individuals and can be accessed via http://biotech-now.org/humanitarian-award-nomination.  Nominees will be evaluated and judged on the following criteria: Impact on future generations; Impact on contemporary society; Contribution to the field of biotechnology; and Level of innovation exhibited.

    Qualified nominees for the Biotech Humanitarian Award will be professionals in the biotechnology field including scientists, researchers, academics, entrepreneurs, financiers, philanthropists, educators, advocates and others who have added value to society through their pursuit of biotechnology processes.

    Drug Patent Expirations in March 2011

    *Drugs may be covered by multiple patents

    TradenameApplicantGeneric NamePatent Number Patent Expiration
    AZOPTAlconbrinzolamide5,240,923*PEDMar 1, 2011
    SYMLINAmylinpramlintide acetate6,610,824Mar 3, 2011
    NITROLINGUAL PUMPSPRAYPohl Boskampnitroglycerin5,186,925Mar 6, 2011
    SYMLINAmylinpramlintide acetate6,610,824Mar 8, 2011
    SYMLINAmylinpramlintide acetate7,407,934Mar 8, 2011
    SYMLINAmylinpramlintide acetate5,998,367Mar 8, 2011
    VANTASEndo Pharmhistrelin acetate5,292,515Mar 8, 2011
    SUPPRELIN LAEndo Pharmhistrelin acetate5,292,515Mar 8, 2011
    SYMLINAmylinpramlintide acetate7,271,238Mar 8, 2011
    FOLLISTIMOrganon Usa Incfollitropin alfa/beta5,270,057Mar 20, 2011
    PROSCARMerckfinasteride6,046,183Mar 20, 2011
    FAMVIRNovartisfamciclovir5,246,937*PEDMar 21, 2011
    XALATANPharmacia And Upjohnlatanoprost5,422,368Mar 22, 2011
    XALATANPharmacia And Upjohnlatanoprost5,296,504Mar 22, 2011
    ENTEREGAdoloralvimopan5,250,542Mar 29, 2011

    This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin. Courtesy of DrugPatentWatch.com

    Journal of Commercial BiotechnologyI have selected these management-themed articles from the Journal of Commercial Biotechnology, exploring the practical aspects of product innovation, R&D, patent law and marketing. The collection is divided into distinct sections: Commentary; Policy; Commercial Strategy; Valuation/Licensing; Funding; Intellectual Property; International; and Case Studies.

    These articles are only fully readable for a limited period of time, so please feel free to read, download and forward them on to your colleagues while they are still available.

    You can view the full collection on the Journal’s website: alternatively, the articles included in this collection are listed below:

    Commentary

    Building biotechnology by design: Role of biotechnology in development
    Patrick Nef

    Why data exclusivity is the new patent protection
    Peter J Pitts

    The UK Government’s strategic approach to the biotechnology industry
    Lord Sainsbury

    Policy

    Public–private partnerships in trust-based public health social networking: Connecting organizations for regional disease surveillance (CORDS)
    Louise S Greshama, Leslie A Pray, Suwit Wibulpolprasert, Beverly Trayner

    Building biotechnology in Okinawa
    Yali Friedman

    Startup America: What it includes and opportunities for innovators
    David B Orange

    Commercial Strategy

    Revitalizing portfolio decision-making at Merck Serono S.A.
    Vincent Aurentz, Bernhard Kirschbaum and Markus Thunecke

    Rethinking commercial strategy – A patient-centered commercial model
    Sanjay K Rao

    Building biotechnology teams: Personality does matter
    Anne S York, Kim A McCarthy and Todd C Darnold

    Valuation/Licensing

    Practical approaches to early stage life sciences technology valuations
    Stephen Mayhew

    Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb
    Nigel Borshell and Adrian Dawkes

    Valuation of complex license contracts
    Ralph Villiger and Boris Bogdan

    Finance

    R&D spending and sources of funding of private US biopharmaceutical firms seeking to go public
    David R Williams and Richard W Pouder

    Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industry
    J Leslie Glick

    When should you fire the founder
    William Bains

    Intellectual Property

    Dominating global intellectual property: Overview of patentability in the USA, Europe and Japan
    Thomas J Kowalski, Antonio Maschio and Samuel H Megerditchian

    Kinik: Raising the stakes for importing products derived from US patented processes practised abroad
    Scott B Familant

    International

    Bioentrepreneurship in Japan: Institutional transformation and the growth of bioventures
    Michael J Lynskey

    Biotechnology in Cuba: 20 years of scientific, social and economic progress
    Ernesto López Mola, Ricardo Silva, Boris Acevedo, José A Buxadó, Angel Aguilera and Luis Herrera

    China 10-Point Patent Checklist: Integrating patents into an overall business strategy for a Western manufacturing entity in China
    Catherine Sun, Sharon R Barner and Harold C Wegner

    Commercial Case Study

    Beacon Sciences: Commercialisation from biothreat detection to beauty enhancement
    Rob Hanes, Damon Borich

    The February 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

    Volume 17, Issue 1

    Editorial

    Applying design thinking to biotechnologyPDF
    Yali Friedman

    Commentary

    Building biotechnology by design: An entrepreneur’s perspectivePDF
    Arthur A Boni
    Building biotechnology by design: Role of biotechnology in developmentPDF
    Patrick Nef

    Articles

    Pricing biologics: Issues, strategic priorities and a conceptual modelPDF
    Sanjay K Rao
    Revitalizing portfolio decision-making at Merck Serono S.A. – GenevaPDF
    Vincent Aurentz, Bernhard Kirschbaum, Markus Thunecke
    Global consensus – Need of the hour for genetically modified organisms (GMO) labelingPDF
    Jagadeesan Premanandh
    Beyond investment: Advancing the biotechnology sector in the countries of the Gulf Cooperation Council (GCC)PDF
    Leonard Lerer, Brett Bowman

    Case Study

    Repurposing of the epidermal growth factorPDF
    Ernesto L Mola, José A Buxadó, Luis Herrera
    Biotechnology commercialization: A case study from Central and Eastern EuropePDF
    Dana Ukropcova, Ernest Sturdik
    The developments in the business models of biotechnology in the Central and Eastern European countries: The example of EstoniaPDF
    Margit Suurna

    Legal and Regulatory Updates

    EU Legal and Regulatory UpdatePDF
    Gerry Kamstra